These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 3695478)

  • 21. DNA distributions in human normal, precancerous and cancerous breast tissue. II. Differences in heparin mediated changes in DNA distributions.
    Weiss H; Kunde D; Streller B
    Oncology; 1988; 45(3):214-23. PubMed ID: 3368198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Significant expression of IGFBP2 in breast cancer compared with benign lesions.
    Busund LT; Richardsen E; Busund R; Ukkonen T; Bjørnsen T; Busch C; Stalsberg H
    J Clin Pathol; 2005 Apr; 58(4):361-6. PubMed ID: 15790698
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MCF10AT: a model for the evolution of cancer from proliferative breast disease.
    Dawson PJ; Wolman SR; Tait L; Heppner GH; Miller FR
    Am J Pathol; 1996 Jan; 148(1):313-9. PubMed ID: 8546221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Usual hyperplasia, atypical hyperplasia and carcinoma-in-situ of breast: a morphologic study].
    Kan X; Shen DH; Shi B; He JS
    Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):312-5. PubMed ID: 15363313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CEA and HMFG in hyperplastic and malignant lesions of the breast.
    De Potter CR; Beghin C; Praet MM; Pauwels CF; Roels HJ
    Pathol Res Pract; 1988 Jun; 183(3):271-6. PubMed ID: 2843840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Diseases of the female breast: clinical pathology].
    Torhorst J
    Ther Umsch; 1993 May; 50(5):307-13. PubMed ID: 8397447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HER2 as a prognostic factor in breast cancer.
    Ménard S; Fortis S; Castiglioni F; Agresti R; Balsari A
    Oncology; 2001; 61 Suppl 2():67-72. PubMed ID: 11694790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression and modulation of estrogen receptors in human breast cancer.
    Nenci I
    J Steroid Biochem; 1985 Dec; 23(6B):1093-6. PubMed ID: 4094428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The breast: tissue changes and cancer risk.
    Sinclair RA
    Med J Aust; 1988 Oct; 149(8):424-6. PubMed ID: 3173205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathologic analysis of breast lesions associated with multiple papillomas.
    Ali-Fehmi R; Carolin K; Wallis T; Visscher DW
    Hum Pathol; 2003 Mar; 34(3):234-9. PubMed ID: 12673557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Significance of proliferative breast lesions around breast cancers].
    Moriya T; Manabe T; Sakurai T; Sakamoto K
    Gan To Kagaku Ryoho; 1995 Apr; 22 Suppl 1():42-5. PubMed ID: 7747991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Microsatellite instability and allele-specific chromosome 3p deletion in breast cancer and precancerous lesions].
    Fu Q; Yao GY; Tang XL; Chen LR; Zheng ZX
    Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):34-40. PubMed ID: 17575691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of caspases 3, 6 and 8 is increased in parallel with apoptosis and histological aggressiveness of the breast lesion.
    Vakkala M; Pääkkö P; Soini Y
    Br J Cancer; 1999 Oct; 81(4):592-9. PubMed ID: 10574243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Ductal carcinoma in situ: steroid receptors and proliferation kinetics].
    Ronay G; Sponsel N; Tulusan AH
    Pathologe; 1990 Nov; 11(6):327-31. PubMed ID: 1963219
    [No Abstract]   [Full Text] [Related]  

  • 36. Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention.
    Fabian CJ; Kimler BF
    Ann N Y Acad Sci; 2001 Dec; 952():44-59. PubMed ID: 11795443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct action of estrogen on sequence of progression of human preneoplastic breast disease.
    Shekhar MP; Nangia-Makker P; Wolman SR; Tait L; Heppner GH; Visscher DW
    Am J Pathol; 1998 May; 152(5):1129-32. PubMed ID: 9588879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stereotaxic fine needle aspiration cytology of clinically occult malignant and premalignant breast lesions.
    Bibbo M; Scheiber M; Cajulis R; Keebler CM; Wied GL; Dowlatshahi K
    Acta Cytol; 1988; 32(2):193-201. PubMed ID: 2831687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinicopathological characteristics of atypical cystic duct (ACD) of the breast: assessment of ACD as a precancerous lesion].
    Fu L; Fu XY; Kusama R; Matsuyama I; Liu TH; Tsuchiya S
    Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):221-4. PubMed ID: 15256112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical profile of the estrogen and progesterone receptors in mammary benign lesions.
    Moise M; Răducan S; Boscu A; Jianu A; Niculescu M; Selaru M; Motoc A
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(3):875-82. PubMed ID: 23272545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.